CGON

Cg Oncology, Inc.

A clinical-stage oncolytic immunotherapy company, CG Oncology develops genetically engineered viruses that selectively infect and destroy bladder cancer cells while rallying the body's immune system to attack tumors. Its lead candidate, cretostimogene, is designed to treat bladder cancer while sparing patients from bladder-removal surgery. Founded in California in 2010 as Cold Genesys — a name born from its virus-based technology — the company rebranded as CG Oncology in 2020, keeping "CG" as a nod to its origins.

CUSIP: 156944100HealthcareUS1 holder

Ownership Activity Financials Filings

CGON

CGON

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Other Events

Regulation FD Disclosure